{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-029038","form_type":"8-K","ticker":"ANIP","cik":"0001023024","company_name":"ANI PHARMACEUTICALS INC","filed_at":"2023-03-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:43.545681+00:00","generated_at":"2026-06-18T10:58:18.895587+00:00","sec_items":["5.03","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"confidence":"high","headline":"ANI Pharmaceuticals amends bylaws to adopt universal proxy rules, update DGCL provisions, add forum selection clause","bullets":["Board approved Second Amended and Restated Bylaws effective Feb 28, 2023, incorporating universal proxy rules and recent DGCL amendments.","Quorum for stockholder meetings (other than Board-called) changed to majority of voting power; stockholder list requirement removed.","Enhanced disclosure and procedural requirements for stockholder proposals and director nominations, including universal proxy compliance.","Indemnification provisions updated with mandatory advancement of expenses subject to Board consent; forum selection clause added for Delaware and federal courts."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-029038","json":"https://secwatch.observer/filing/0001104659-23-029038.json","markdown":"https://secwatch.observer/filing/0001104659-23-029038.md","text":"https://secwatch.observer/filing/0001104659-23-029038.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1023024/000110465923029038/0001104659-23-029038-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1023024/000110465923029038/tm238560d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T10:58:18.895587+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f0f28de5dc1f3eeb5f91bca99094cee9932dd928","claim":"ANI PHARMACEUTICALS INC: Board adopted Second Amended and Restated Bylaws with clarifying amendments, updates for universal proxy rules and DGCL, including changes to quorum requirements, stockholder proposal procedures, director nomination procedures, indemnification provisions, and a forum selection clause (effective 2023-02-28).","evidence_excerpt":"On February 28, 2023, the Board of Directors (the “Board”) of ANI Pharmaceuticals, Inc. (the “Company”) approved the Second Amended and Restated Bylaws of the Company (the “Bylaws”), which became effective immediately.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1023024/000110465923029038/0001104659-23-029038-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"bylaw amendment"},{"label":"Effective","value":"2023-02-28"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}